Clinical trials: CTLA-4
Glioblastoma, GBM
Surgical Nivolumab And Ipilimumab For Recurrent GBM
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
- Trial name
- NCT04606316
- Testing
- Nivolumab, Ipilimumab, Surgery
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Gilbert Youssef
Lung Adenocarcinoma
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive…
- Trial name
- PHOENIX (NCT07416058)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Guangdong Association of Clinical Trials
MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy…
- Trial name
- NCT06549907
- Testing
- Multi-omics testing, MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Adenocarcinoma, Prostate Carcinoma
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body.
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer
- Trial name
- NCT00170157
- Testing
- Bicalutamide, Flutamide, Goserelin Acetate
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Mayo Clinic
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
Squamous Cell Carcinoma of the Head and Neck
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with…
- Trial name
- NCT04326257
- Testing
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dan Zandberg
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Head/Neck Neoplasm
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or…
- Trial name
- NCT03952065
- Testing
- PD1/PDL1/CTLA4 inhibitors
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Melanoma
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor.
- Trial name
- NCT00972933
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Diwakar Davar
PI3KCD, CTLA4
Novel Genetic Disorders of the Immune System
Background: The immune system helps the body fight infection and disease. People with immune system problems can get infections, blood disorders, and other health problems.
- Conditions
- PI3KCD, CTLA4, STAT3GOF, MAGT1
- Trial name
- NCT02257892
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety of RG2077 in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves.
- Trial name
- NCT00076934
- Testing
- RG2077 (CTLA4-IgG4m)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stage III (Unresectable) or Stage IV Advanced Melanoma
Expanded Access Program With Nivolumab to Treat Melanoma
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
- Trial name
- Checkmate 168 (NCT02142218)
- Testing
- Nivolumab
- Where
- 80 sites in United States, Argentina and 4 more
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis, Myocardial Inflammation
Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
This study aims to evaluate the effects of abatacept, a CTLA4-Ig fusion protein that binds cluster of differentiation antigen 80 (CD80)/86 (B7-1/B7-2), on subclinical myocarditis in rheumatoid arthritis (RA) through its effect on…
- Trial name
- AMiRA (NCT03619876)
- Testing
- Abatacept, Adalimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Primary Biliary Cirrhosis
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol…
- Trial name
- PBC (NCT02078882)
- Testing
- abatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Christopher Bowlus, MD
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso
Ovarian Cancer
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
This is a randomized, open, comparative, multi-centre study which will recruit up to 66 patients. The objective is mainly to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with…
- Trial name
- INeOV (NCT03249142)
- Testing
- ARM A Durvalumab/chemotherapy association, ARM B Durvalumab/Tremelimumab/chemotherapy association
- Where
- 11 sites in France
- Volunteers
- 69 people
- Sponsor
- ARCAGY/ GINECO GROUP
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects.
- Trial name
- NCT05559554
- Testing
- AK104 (before the change), AK104 (after the change)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Akeso
Locally Advanced and Metastatic Pancreatic Cancer
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer
- Trial name
- NCT04324307
- Testing
- PD-L1/CTLA4 BsAb, GP, FOLFIRINOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Colorectal Cancer Metastatic
Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC
Colo-rectal cancer is still one of the leading causes of cancer death worldwide. In France, approximately 40 500 new cases are diagnosed each year.
- Trial name
- MEDITREME (NCT03202758)
- Testing
- Durvalumab, Tremelimumab and ,FOLFOX
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Georges Francois Leclerc